Inmune Bio, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2017 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Inmune Bio, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2017 to Q4 2023.
  • Inmune Bio, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $19.6M, a 42.8% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $19.6M +$5.87M +42.8% Dec 31, 2023 10-K 2024-03-28
Q4 2022 $13.7M +$6.94M +102% Dec 31, 2022 10-K 2024-03-28
Q4 2021 $6.79M +$3.25M +91.5% Dec 31, 2021 10-K 2023-03-02
Q4 2020 $3.55M +$1.64M +85.9% Dec 31, 2020 10-K 2022-03-03
Q4 2019 $1.91M +$241K +14.5% Dec 31, 2019 10-K 2021-03-04
Q4 2018 $1.67M +$1.49M +829% Dec 31, 2018 10-K 2020-03-11
Q4 2017 $179K Dec 31, 2017 10-K 2019-03-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.